Target motion variability and on-line positioning accuracy during external-beam radiation therapy of prostate cancer with an endorectal balloon device

Strahlentherapie und Onkologie

Volumn 182, Issue 9, 2006, Pages 531-536

  El Bassiouni, Mazen ^a,b   Davis, J Bernard ^a   El Attar, Inas ^c   Studer, Gabriela M ^a   Lütolf, Urs M ^a   Ciernik, I Frank ^a,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Cairo University   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Endorectal balloon; Intensity modulation; Position accuracy; Prostate cancer; PTV

Indexed keywords

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; ENDORECTAL BALLOON; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MEDICAL INSTRUMENTATION; PROSTATE CANCER; PUBIS SYMPHYSIS; RADIOLOGICAL PROCEDURES;

AGED; BALLOON DILATATION; CONFIDENCE INTERVALS; HUMANS; MALE; MOVEMENT; POSTURE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RECTUM; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33748193514     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-006-1581-1     Document Type: Article

References (35)

1. Alasti H, Petric MP, Catton CN, et al. Portal imaging for evaluation of daily on-line setup errors and off-line organ motion during conformal irradiation of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:869-84.
2. Bakai A, Paulsen F, Plasswilm L, et al. [Positioning accuracy in conformational prostatic irradiation using portal imaging.] Strahlenther Onkol 2002;178:84-90.
3. Baumert BG, Zagralioglu O, Davis JB, et al. The use of a leg holder immobilisation device in 3D-conformal radiation therapy of prostate cancer. Radiother Oncol 2002;65:47-52.
4. Beard CJ, Kijewski P, Bussiere M, et al. Analysis of prostate and seminal vesicle motion: implications for treatment planning. Int J Radiat Oncol Biol Phys 1996;34:451-8.
5. Beckendorf V, Guerif S, Le Prise E, et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 2004;60:1056-65.
6. Cavey ML, Bayouth JE, Colman M, et al. IMRT to escalate the dose to the prostate while treating the pelvic nodes. Strahlenther Onkol 2005;181:431-41.
7. Ciernik IF, Baumert BG, Egli P, et al. On-line correction of beam portals in the treatment of prostate cancer using an endorectal balloon device. Radiother Oncol 2002;65:39-45.
8. D'Amico AV, Manola J, Loffredo M, et al. A practical method to achieve prostate gland immobilization and target verification for daily treatment. Int J Radiat Oncol Biol Phys 2001;51:1431-6.
9. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005;92:488-98.
10. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267-72.
11. De Meerleer G, Vakaet L, De Gersem W, et al. Direct segment aperture and weight optimization for intensity-modulated radiotherapy of prostate cancer. Strahlenther Onkol 2004;180:136-43.
12. Galalae RM, Loch T, Riemer B, et al. Health-related quality of life measurement in long-term survivors and outcome following radical radiotherapy for localized prostate cancer. Strahlenther Onkol 2004;180:582-9.
13. Ganswindt U, Paulsen F, Anastasiadis AG, et al. 70 Gy or more: which dose for which prostate cancer? J Cancer Res Clin Oncol 2005;131:407-19.
14. Gerstner N, Wachter S, Dorner D, et al. [Significance of a rectal balloon as internal immobilization device in conformal radiotherapy of prostatic carcinoma.] Strahlenther Onkol 1999;175:232-8.
15. Hille A, Schmidberger H, Tows N, et al. The impact of varying volumes in rectal balloons on rectal dose sparing in conformal radiation therapy of prostate cancer. A prospective three-dimensional analysis. Strahlenther Onkol 2005;181:709-16.
16. ICRU Report 62. Perscribing, recording, and reporting photon beam therapy (Supplement to ICRU Report 50). Bethesda: ICRU, 1999.
17. Kupelian PA, Thakkar VV, Khuntia D, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005;63:1463-8.
18. Langen KM, Jones DT. Organ motion and its management. Int J Radiat Oncol Biol Phys 2001;50:265-78.
19. Litzenberg D, Dawson LA, Sandler H, et al. Daily prostate targeting using implanted radiopaque markers. Int J Radiat Oncol Biol Phys 2002;52:699-703.
20. Mavroidis P, Al-Abany M, Helgason AR, et al. Dose-response relations for anal sphincter regarding fecal leakage and blood or phlegm in stools after radiotherapy for prostate cancer. Radiobiological study of 65 consecutive patients. Strahlenther Onkol 2005;181:293-306.
21. McGary JE, Teh BS, Butler EB, et al. Prostate immobilization using a rectal balloon. J Appl Clin Med Phys 2002;3:6-11.
22. Mock U, Bogner J, Georg D, et al. Comparative treatment planning on localized prostate carcinoma: conformal photon- versus proton-based radiotherapy. Strahlenther Onkol 2005;181:448-55.
23. Patel RR, Orton N, Tome WA, et al. Rectal dose sparing with a balloon catheter and ultrasound localization in conformal radiation therapy for prostate cancer. Radiother Oncol 2003;67:285-94.
24. Patel RR, Tomé WA, Orton N, et al. The use of an endorectal balloon catheter and ultrasound localization in conformal radiation therapy for prostate cancer: a DVH analysis of rectal dose-sparing with 3D-CRT, IMRT, and helical tomotherapy. Int J Radiat Oncol Biol Phys 2002;54:Suppl 1:259.
25. Perez CA, Michalski JM, Purdy JA, et al. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison. Int J Radiat Oncol Biol Phys 2000;47:629-37.
26. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
27. Roeske JC, Forman JD, Mesina CF, et al. Evaluation of changes in the size and location of the prostate, seminal vesicles, bladder, and rectum during a course of external beam radiation therapy. Int J Radiat Oncol Biol Phys 1995;33:1321-9.
28. Stroom JC, Koper PC, Korevaar GA, et al. Internal organ motion in prostate cancer patients treated in prone and supine treatment position. Radiother Oncol 1999;51:237-48.
29. Van Herk M, Bruce A, Kroes AP, et al. Quantification of organ motion during conformal radiotherapy of the prostate by three-dimensional image registration. Int J Radiat Oncol Biol Phys 1995;33:1311-20.
30. Van Lin EN, Hoffmann AL, van Kollenburg P, et al. Rectal wall sparing effect of three different endorectal balloons in 3D conformal and IMRT prostate radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:565-76.
31. Van Lin EN, van der Vight LP, Witjes JA, et al. The effect of an endorectal balloon and off-line correction on the interfraction systematic and random prostate position variations: a comparative study. Int J Radiat Oncol Biol Phys 2005;61:278-88.
32. Wachter S, Gerstner N, Dorner D, et al. The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002; 52:91-100.
33. Wu J, Haycocks T, Alasti H, et al. Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiother Oncol 2001;61:127-33.
34. Zelefsky MJ, Crean D, Mageras GS, et al. Quantification and predictors of prostate position variability in 50 patients evaluated with multiple CT scans during conformal radiotherapy. Radiother Oncol 1999;50:225-34.
35. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9.